Claims
- 1. A polymeric network consisting essentially of cross linked poly(propylene fumarate).
- 2. A poly(propylene fumarate) cross linked with diacrylate.
- 3. A cross linkable composition comprising poly(propylene fumarate)-diacrylate.
- 4. A polymeric network comprising poly(propylene fumarate) cross linked with poly(propylene fumarate)-diacrylate.
- 5. The composition according to claim 4 having a compressive strength at yield of at least 11.7 MPa.
- 6. The composition according to claim 4 having a compressive modulus of at least 66.4 MPa.
- 7. The composition according to claim 4 wherein said composition degrades to a hydrophilic polymer capable of being passively excreted by human kidneys.
- 8. The composition according to claim 4 wherein the cross linked poly(propylene fumarate)-diacrylate has an equilibrium water content less than 1.5 percent by weight.
- 9. A composition suitable for use as a biocompatible implant, comprising:
a poly(propylene fumarate) network crosslinked with diacrylate macromers.
- 10. The composition according to claim 9 having a compressive strength at yield of at least 1 1.7 MPa.
- 11. The composition according to claim 9 having a compressive modulus of at least 66.4 MPa.
- 12. The composition according to claim 9 wherein said composition degrades to a hydrophilic polymer capable of being passively excreted by human kidneys.
- 13. A poly(propylene fumarate) network crosslinked with diacrylate and suitable for use as a biocompatible implant, having the formula:
- 14. A method of making a poly(propylene fumarate) network, comprising:
(a) forming a propylene fumarate; (b) transesterifying the PF to give poly(propylene fumarate); (c) synthesizing poly(propylene fumarate)-diacrylate by reacting the poly(propylene fumarate) with an acrylation reagent; and (d) cross-linking the poly(propylene fumarate)-diacrylate.
- 15. The method according to claim 14 wherein step (a) comprises forming di(2-hydroxylpropyl) fumarate by the reaction of fumaryl chloride with propylene glycol.
- 16. The method according to claim 14 wherein the acrylation reagent in step (c) comprises acryloyl chloride.
- 17. The method according to claim 14 wherein the cross linked poly(propylene fumarate)-diacrylate has a compressive strength of at least 11.7 MPa.
- 18. The method according to claim 14 wherein the cross linked poly(propylene fumarate)-diacrylate has an equilibrium water content less than 1.5 percent by weight.
- 19. The method according to claim 14 wherein the poly(propylene fumarate) network degrades to a hydrophilic polymer capable of being passively excreted by human kidneys.
RELATED CASES
[0001] The present case claims the benefit of U.S. provisional applications Serial No. 60/129577, filed Apr. 16, 1999, and entitled “Development of Biodegradable Bone Cement Based on Poly(Propylene Fumarate) and a Macromer,” Serial No. 60/146,991, filed Aug. 3, 1999, and entitled “Synthesis of Poly (Propylene Fumarate) by Acylation of Propylene Glycol in the Presence of a Proton Scavenger,” Serial No. 60/167,328, filed Nov. 24, 1999, and entitled “Preparation of an Injectable, in situ Polymerizable and Biodegradable Biomaterial Based On Poly(Propylene Fumarate) and Biodegradable Crosslinking Reagents,” and Serial No. 60/167,388, filed Nov. 24, 1999, and entitled “Injectable Biodegradable Polymer Composites Based on Poly(Propylene Fumarate) Crosslinked with Poly(Ethylene Glycol)-Dimetbacrylate and β-Tricalcium Phosphate,” all of which are incorporated herein by reference.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] This work was funded by the National Institutes of Health R01-AR44381 and R01-DE13031.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09549485 |
Apr 2000 |
US |
Child |
10127117 |
Apr 2002 |
US |